Cumberland Pharmaceuticals Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.2% | -1.5% | +24.6% | -1.0% | -15.6% | +8.9% | -3.9% | +16.7% | -5.9% | -4.3% | +17.6% | |
| – | -1.7% | +19.9% | +23.7% | +0.1% | +0.6% | +16.6% | +1.8% | +3.5% | -33.5% | +8.6% | +1.2% | |
| – | -10.4% | -5.2% | +24.8% | -1.2% | -19.2% | +6.8% | -5.6% | +21.0% | +1.8% | -6.6% | +21.0% | |
| – | +13.5% | -17.1% | +22.3% | +87.6% | -6.2% | -15.9% | -1.5% | +17.7% | -12.8% | -17.4% | +15.6% | |
| – | -9.5% | +12.5% | +17.2% | +3.7% | -4.1% | +2.2% | -4.1% | +4.1% | +4.6% | +4.5% | +7.4% | |
| – | -3.0% | +3.9% | +32.8% | +7.6% | -11.0% | -3.0% | -0.9% | +10.7% | +11.5% | -12.4% | +7.8% | |
| – | -131.2% | – | – | – | – | – | – | – | – | – | – | |
| – | +10.1% | +44.1% | -12.7% | +110.8% | +25.7% | +7.1% | -62.8% | +497.8% | +14.0% | -9.3% | -18.1% | |
| – | -66.7% | -207.1% | – | – | – | – | – | – | – | – | – | |
| – | -58.3% | -157.5% | – | -99.6% | -576.8% | – | -37.6% | +97.3% | -33.5% | -149.5% | – | |
| – | -69.8% | -229.2% | – | – | – | – | – | – | – | – | – | |
| – | -37.8% | -67.2% | -197.1% | – | – | – | – | – | +646.6% | -92.7% | +1,521.2% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.